Home > People > Faculty > Profiles > Herbert Pang, PhD

Herbert Pang, PhD

share
Print

email this


Adjunct Assistant Professor of Biostatistics and Bioinformatics
Department:
Biostatistics & Bioinformatics
E-mail:
firstname.lastname@duke.edu
Address:
Duke Box 2721
Durham, NC 27710
Training:
  • PhD, Yale University, 2008
Research Interests:
Classification and Predictive Models
Design and Analysis of Biomarker Clinical Trials
Genomics
Pathway Analysis
Software:
Pathway Analysis using Random Forests
Regularized Shrinkage-Based Diagonal Discriminant Analysis
Survival Gene Selection using Iterative Recursive Feature Elimination
Pathway analysis for survival data
Sample Size Considerations of Prediction-Validation Methods for Survival Outcomes
Professional Services :
Editorial Board, Journal of Clinical Oncology
Representative Publications:
  • Balajonda N, Bisanar TL, Mathew JP, Pang H, Voils CI. Determinants of a subject's decision to participate in clinical anesthesia research. Anesth Analg. 2013 Feb;116(2):448-54.  Abstract
  • Garrett ME, Abdelmalek MF, Ashley-Koch A, Hauser MA, Moylan CA, Pang H, Diehl AM, Tillmann HL. IL28B rs12979860 is not associated with histologic features of NAFLD in a cohort of Caucasian North American patients. J Hepatol. 2013 Feb;58(2):402-3.  Abstract
  • Kelley MJ, Bogart JA, Hodgson LD, Ansari RH, Atkins JN, Pang H, Green MR, Vokes EE. Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206. J Thorac Oncol. 2013 Jan;8(1):102-8.  Abstract
  • Pang H, Jung SH. Sample Size Considerations of Prediction-Validation Methods in High-Dimensional Data for Survival Outcomes. Genet Epidemiol. 2013 Mar 7.  Abstract
  • Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CL, . Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013 Apr 3;309(13):1359-67.  Abstract
  • Uronis HE, Bendell JC, Altomare I, Blobe GC, Hsu SD, Morse MA, Pang H, Zafar SY, Conkling P, Favaro J, Arrowood CC, Cushman SM, Meadows KL, Brady JC, Nixon AB, Hurwitz HI. A Phase II Study of Capecitabine, Oxaliplatin, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas. Oncologist. 2013;18(3):271-2.  Abstract
  • Dudek AZ, Pang H, Kratzke RA, Otterson GA, Hodgson L, Vokes EE, Kindler HL, . Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report. J Thorac Oncol. 2012 Apr;7(4):755-9.  Abstract
  • Kim I, Pang H, Zhao H. Bayesian semiparametric regression models for evaluating pathway effects on continuous and binary clinical outcomes. Stat Med. 2012 Jul 10;31(15):1633-51.  Abstract
  • Kong TS, Laidler KJ, Pang H. Relationship type, condom use and HIV/AIDS risks among men who have sex with men in six Chinese cities. AIDS Care. 2012;24(4):517-28.  Abstract
  • Pang H, George SL, Hui K, Tong T. Gene Selection using Iterative Feature Elimination Random Forests for Survival Outcomes. IEEE/ACM Trans Comput Biol Bioinform. 2012 Apr 26.  Abstract
  • Syn WK, Agboola KM, Swiderska M, Michelotti GA, Liaskou E, Pang H, Xie G, Philips G, Chan IS, Karaca GF, Pereira Tde A, Chen Y, Mi Z, Kuo PC, Choi SS, Guy CD, Abdelmalek MF, Diehl AM. NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease. Gut. 2012 Sep;61(9):1323-9.  Abstract
  • Altomare I, Bendell JC, Bullock KE, Uronis HE, Morse MA, Hsu SD, Zafar SY, Blobe GC, Pang H, Honeycutt W, Sutton L, Hurwitz HI. A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. Oncologist. 2011;16(8):1131-7.  Abstract
  • Pang H, Hauser M, Minvielle S. Pathway-based identification of SNPs predictive of survival. Eur J Hum Genet. 2011 Jun;19(6):704-9.  Abstract
  • Ready NE, Dudek AZ, Pang HH, Hodgson LD, Graziano SL, Green MR, Vokes EE. Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. J Clin Oncol. 2011 Nov 20;29(33):4436-41.  Abstract
  • Wong NS, Fernando NH, Bendell JC, Morse MA, Blobe GC, Honeycutt W, Pang H, Hurwitz HI. A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer. 2011 Sep;10(3):210-6.  Abstract
  • Wong NS, Fernando NH, Nixon AB, Cushman S, Aklilu M, Bendell JC, Morse MA, Blobe GC, Ashton J, Pang H, Hurwitz HI. A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. Anticancer Res. 2011 Jan;31(1):255-61.  Abstract
  • Dubey S, Jänne PA, Krug L, Pang H, Wang X, Heinze R, Watt C, Crawford J, Kratzke R, Vokes E, Kindler HL. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol. 2010 Oct;5(10):1655-61.  Abstract
  • Miller AA, Pang H, Hodgson L, Ramnath N, Otterson GA, Kelley MJ, Kratzke RA, Vokes EE, . A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602). J Thorac Oncol. 2010 Mar;5(3):380-4.  Abstract
  • Otterson GA, Hodgson L, Pang H, Vokes EE, . Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). J Thorac Oncol. 2010 Oct;5(10):1644-8.  Abstract
  • Pang H, Datta D, Zhao H. Pathway analysis using random forests with bivariate node-split for survival outcomes. Bioinformatics. 2010 Jan 15;26(2):250-8.  Abstract
  • Pang H, Ebisu K, Watanabe E, Sue LY, Tong T. Analysing breast cancer microarrays from African Americans using shrinkage-based discriminant analysis. Hum Genomics. 2010 Oct;5(1):5-16.  Abstract
  • Pang H, Tong T, Zhao H. Shrinkage-based diagonal discriminant analysis and its applications in high-dimensional data. Biometrics. 2009 Dec;65(4):1021-9.  Abstract
  • Pang H, Zhao H. Building pathway clusters from Random Forests classification using class votes. BMC Bioinformatics. 2008;9:87.  Abstract
  • Pang H, Lin A, Holford M, Enerson BE, Lu B, Lawton MP, Floyd E, Zhao H. Pathway analysis using random forests classification and regression. Bioinformatics. 2006 Aug 15;22(16):2028-36.  Abstract